Advancing Treatment of Disease with Innovative protein therapeutics and Technologies
Scientific Advisory Board
Therapure Innovations is honored to have a Scientific Advisory Board (SAB) made up of internationally recognized experts in their fields. They provide insight and guidance on the most important scientific and clinical issues relevant to the development of the Therapure Innovations pipeline, which includes the therapeutic areas of anemia, oncology, inflammation and transplantation.
Scientific Advisory Board Chair
Gary Levy, MD, FRCPC, BSc
Dr. Levy is Senior Scientist at the Toronto General Research Institute. He graduated from the University of Toronto’s medical school in 1973 and subsequently completed his specialty in hepatology there in 1978. He completed his postdoctoral studies in immunology in 1981 at the Scripps Clinic and Research Foundation (now Scripps Research Institute). A many-time award winner, a visionary and an internationally recognized hepatologist, Dr. Levy founded the Liver Transplant Unit and cofounded the Multi-Organ Transplant Unit at the Toronto General Hospital/University Health Network and served as its medical director until September 2013. Dr. Levy also cofounded Trillium Therapeutics Inc., a Canadian biopharmaceutical company, and served as its Chief Scientific Officer until 2002. In recognition of his pioneering work in living donor liver transplants in Canada and establishing one of the largest transplant programs in the world, Dr. Levy received the Order of Ontario, the province's highest honor, on February 3, 2015.
Scientific Advisory Board Members
Bernard Chiasson, PhD
Dr. Chiasson is President of BJC Integrated Scientific Management Inc. and Chief Scientific Officer at Tribute Pharmaceuticals Inc. He earned his PhD in pharmacology and neuroscience from Dalhousie University and completed his postdoctoral studies at the University of Toronto. In his two decades in the biopharmaceutical and life sciences industry, working at industry notables such as Amgen Inc., Bayer Inc. and Novartis Pharmaceuticals Canada Inc., he has amassed experience in drug discovery, medical affairs, regulatory affairs and licensing, as well as strategic business development and executive management.
David Cosgrove, MBBCh
Dr. Cosgrove is Assistant Professor of Oncology at the Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center. He graduated with his medical degree (MBBCh) from the Faculty of Medicine at the National University of Ireland in 2000, which he followed with a residency at James Connolly Memorial Hospital (now Connolly Hospital) and a residency and fellowship at the Johns Hopkins University School of Medicine (2009). His research is focused on the use of molecular biomarkers in cancer cells to improve therapeutic strategies on an individual patient basis, and he has authored numerous publications with a focus on medical oncology.
John Glaspy, MD, MPH
Dr. Glaspy is Professor of Medicine and a physician at the Jonsson Comprehensive Cancer Center (JCCC) of the University of California, Los Angeles (UCLA) School of Medicine. He is director of the Clinical Research Unit and the Women’s Cancer Research Program at JCCC, where he also holds a Chair in Cancer Research. Dr. Glaspy received his MD from the UCLA School of Medicine and his Master of Public Health (MPH) from the UCLA Fielding School of Public Health. His research is focused on new approaches to the treatment of breast cancer and malignant melanoma. Dr. Glaspy is a highly regarded specialist in hematology and oncology, and he has received numerous awards and honors.
A. Gerson Greenburg, MD, PhD, FACS
Dr. Greenburg is a Professor Emeritus of Surgery at Brown University, where he was a professor of surgery for 20 years. He completed his MD at the University of Chicago in 1963 and later earned his PhD in industrial engineering/management sciences at Northwestern University. His 52-year career reflects a specialty in surgery, with transfusion medicine and the application of computerization to medical practice featuring prominently. He has received numerous awards and chaired multiple professional committees. He sits on many editorial boards and has applied his considerable expertise to several corporate roles.
Jennifer J. Knox, MD, FRCPC, MSc
Dr. Knox is Associate Professor of Medicine at the University of Toronto and Staff Medical Oncologist at the Princess Margaret Hospital/University Health Network. She completed her medical degree and an MSc in molecular biology at the University of Toronto in 1995 and 1991, respectively. After completing her medical oncology specialty training, she completed a fellowship at Princess Margaret, which focused on new drug development and clinical trials. Her expertise includes gastrointestinal and genitourinary malignancies, and she has participated in or chaired many local and international trials. She also cochairs working groups at the National Cancer Institutes of the US and Canada and has been nominated as Chair of the Cancer Committee at the Princess Margaret Cancer Centre for 2015 and 2016.
Ian McGilvray, MD, FRCSC, PhD
Dr. McGilvray is Associate Professor in the Department of Surgery at the University of Toronto. He is also a scientist in the Division of Experimental Therapeutics, Toronto General Research Institute and a member of the Princess Margaret Gastrointestinal Site Group, a team of internationally recognized experts who assess, plan treatment and deliver care to patients with cancers of the gastrointestinal system. Dr. McGilvray earned his medical degree at McGill University in 1993 and later completed a PhD in cell biology. His expertise is in diseases of the liver, particularly viral hepatitis, and in targeting the liver with novel technologies such as nanoparticles. His clinical focus is devoted to transplantation and complex oncology of the liver and pancreas. He was named one of Toronto’s best doctors in a 2014 survey by Toronto Life magazine.
To learn more about our areas of research, platform technologies and pipeline products, or to explore opportunities to partner and/or collaborate with us to improve existing therapeutics, please contact us at firstname.lastname@example.org.